Capricor Therapeutics (CAPR): Roth Capital Experts See 192% Price Potential!
Reading Time: 2 minutes
Capricor Therapeutics (CAPR) is a biotechnology company focused on cell and exosome-based therapies for rare diseases. The company presented its Q1 report after hours on May 13. According to the report, a net loss of $24.4 million was recorded, with no revenue during the reporting period. Despite the loss, the company has a solid liquidity position of approximately $145 million, which is expected to support planned operations until 2027. Progress on Deramiocel Capricor's main product, Deramiocel, is in the late stages of development for the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
